和邦生物
(603077)
| 流通市值：192.52亿 | | | 总市值：192.52亿 |
| 流通股本：88.31亿 | | | 总股本：88.31亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,926,520,025.82 | 3,921,052,446.51 | 1,725,715,319.77 | 8,547,476,550.13 |
| 营业收入 | 5,926,520,025.82 | 3,921,052,446.51 | 1,725,715,319.77 | 8,547,476,550.13 |
| 二、营业总成本 | 5,726,755,746.57 | 3,858,427,658.1 | 1,693,064,580.46 | 8,490,183,101.47 |
| 营业成本 | 5,260,558,534.55 | 3,550,560,477.59 | 1,541,010,536.39 | 7,880,674,861.75 |
| 税金及附加 | 51,463,992.97 | 38,991,187.68 | 15,281,731.22 | 69,244,050.1 |
| 销售费用 | 64,041,100.06 | 42,247,961.36 | 18,461,525.73 | 79,251,228.32 |
| 管理费用 | 289,279,526.44 | 189,474,984.15 | 98,313,507.2 | 415,405,917.14 |
| 研发费用 | 12,370,674.89 | 8,308,956.21 | 4,536,209.31 | 30,625,896.07 |
| 财务费用 | 49,041,917.66 | 28,844,091.11 | 15,461,070.61 | 14,981,148.09 |
| 其中:利息费用 | 86,395,013.74 | 57,018,733.59 | 27,558,396.96 | 66,987,144 |
| 其中:利息收入 | 41,079,771.87 | 25,332,309.96 | 10,380,396.9 | 47,050,375.06 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -4,217,703.42 | 302,393.09 | -1,621,149.03 | -5,670,300.35 |
| 资产处置收益 | 1,237,084.79 | 1,237,409.73 | 1,238,730.99 | 1,168,756.89 |
| 资产减值损失(新) | -14,319,120.94 | -6,302,681.31 | -8,439,376.79 | -128,021,291.49 |
| 信用减值损失(新) | -22,193,435.84 | -10,738,651.92 | -7,366,037.14 | -2,689,460.22 |
| 其他收益 | 24,537,991.6 | 8,399,822.54 | 4,421,189.35 | 16,126,285.6 |
| 四、营业利润 | 184,809,095.44 | 55,523,080.54 | 20,884,096.69 | -61,792,560.91 |
| 加:营业外收入 | 60,192.18 | 29,298.72 | 1,262.69 | 1,072,193.37 |
| 减:营业外支出 | 14,447,846.07 | 571,334.84 | 241,348.28 | 4,963,194.52 |
| 五、利润总额 | 170,421,441.55 | 54,981,044.42 | 20,644,011.1 | -65,683,562.06 |
| 减:所得税费用 | 93,978,527.11 | 14,741,612.06 | 13,108,894.2 | 5,061,047.87 |
| 六、净利润 | 76,442,914.44 | 40,239,432.36 | 7,535,116.9 | -70,744,609.93 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 76,442,914.44 | 40,239,432.36 | 7,535,116.9 | -70,744,609.93 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 93,108,537.81 | 51,771,523.37 | 12,517,312.95 | 31,464,685.07 |
| 少数股东损益 | -16,665,623.37 | -11,532,091.01 | -4,982,196.05 | -102,209,295 |
| 扣除非经常损益后的净利润 | 89,690,946.39 | 46,980,060.11 | 8,483,951.04 | 23,489,841.95 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.01 | 0 | 0 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0 | 0 |
| 八、其他综合收益 | -18,262,832.26 | -2,688,512.53 | 14,505,248.27 | -56,289,225.8 |
| 归属于母公司股东的其他综合收益 | -18,651,953.83 | -4,088,730.59 | 12,268,350.6 | -56,934,716.93 |
| 九、综合收益总额 | 58,180,082.18 | 37,550,919.83 | 22,040,365.17 | -127,033,835.73 |
| 归属于母公司股东的综合收益总额 | 74,456,583.98 | 47,682,792.78 | 24,785,663.55 | -25,470,031.86 |
| 归属于少数股东的综合收益总额 | -16,276,501.8 | -10,131,872.95 | -2,745,298.38 | -101,563,803.87 |
| 公告日期 | 2025-10-29 | 2025-08-20 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |